4//SEC Filing
Lin Elizabeth Yeu 4
Accession 0001842190-25-000003
CIK 0001819790other
Filed
Dec 16, 7:00 PM ET
Accepted
Dec 17, 4:07 PM ET
Size
10.8 KB
Accession
0001842190-25-000003
Insider Transaction Report
Form 4
Lin Elizabeth Yeu
Chief Medical Officer
Transactions
- Exercise/Conversion
Common Stock
2025-12-15+6,819→ 24,019 total - Sale
Common Stock
2025-12-16$79.50/sh−2,078$165,201→ 21,941 total - Exercise/Conversion
Restricted Stock Units
2025-12-15−6,819→ 20,459 total→ Common Stock (6,819 underlying)
Holdings
- 6,360(indirect: By Spouse)
Common Stock
- 12,040(indirect: By 401(k))
Common Stock
Footnotes (5)
- [F1]The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock.
- [F2]Since the date of the Reporting Person's last report, 9,506 shares previously owned by the Reporting Person's Spouse's Roth IRA were transferred to the Reporting Person's self-directed IRA and are now directly owned.
- [F3]The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
- [F4]Each RSU represents a contingent right to receive one share of the Company's common stock.
- [F5]RSUs granted on November 4, 2024 in connection with the Reporting Person's appointment as Chief Medical Officer. 25% of the RSUs will vest on December 15th of each of 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service.
Documents
Issuer
Tarsus Pharmaceuticals, Inc.
CIK 0001819790
Entity typeother
Related Parties
1- filerCIK 0001842190
Filing Metadata
- Form type
- 4
- Filed
- Dec 16, 7:00 PM ET
- Accepted
- Dec 17, 4:07 PM ET
- Size
- 10.8 KB